LexaGene Enters into Cooperative Research and Development Agreement with the United States Army’s Combat Capabilities Development Command
September 16 2021 - 7:45AM
LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the
“
Company”), a molecular diagnostics company that
develops fully automated rapid pathogen detection systems, is
pleased to announce it has entered into a Cooperative Research and
Development Agreement (CRADA) with the U.S. Army’s Combat
Capabilities Development Command (DEVCOM)
(https://www.cbc.devcom.army.mil/).
This CRADA aims to foster innovative biothreat defense
capability development, which is part of DEVCOM’s current
technology priorities. LexaGene will work with the United States
Army to demonstrate the capabilities of the MiQLabTM, LexaGene’s
flagship pathogen detection system.
Dr. Manoj Nair, Director Applications & Assay Development at
LexaGene comments, "This CRADA enables our team to work with
biothreat specialists within DEVCOM who have access to unique
biothreat samples and secure government laboratory facilities. This
working arrangement is critical for us to advance our goal of
providing technology for biothreat detection to the United States
government."
Under this agreement, LexaGene will deliver a MiQLab system to
DEVCOM for the purpose of determining the system’s ability to
detect Bacillus anthracis and Yersinia pestis, which cause anthrax
and plague, respectively. DEVCOM will determine the system’s
sensitivity (e.g., limit-of-detection) for these two pathogens as
well as evaluate the system’s quantitative detection
capability.
Dr. Jack Regan, LexaGene’s CEO and Founder states, “Early in my
career, I helped develop the Autonomous Pathogen Detection System
(APDS), which was selected by the U.S. Department of Homeland
Security to be the first autonomous detector component of their
BioWatch antiterrorism program
(https://pubmed.ncbi.nlm.nih.gov/18763806/). Through this work, I
was inspired to improve the APDS technology, so I invented the
technology that LexaGene is now commercializing. LexaGene’s MiQLab
is open-access, making it much more nimble for quickly responding
to a novel threat. I am very pleased to be working again with the
U.S. government and look forward to demonstrating to the Army the
benefits of the MiQLab’s open-access technology for the rapid
detection of bio-threat agents.”
This work will be conducted at both LexaGene and DEVCOM Chemical
Biological Center at Aberdeen Proving Grounds, MD.
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go’. The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately one
hour. The unique open-access feature is designed for custom testing
so that end-users can load their own real-time PCR assays onto the
instrument to target any genetic target of interest.
About U.S. Army Combat Capabilities Development
CommandThe U.S. Army Combat Capabilities Development
Command, known as DEVCOM, is the Army's technology leader and
largest technology developer. DEVCOM ensures the dominance of Army
capabilities by creating, integrating and delivering
technology-enabled solutions to our Soldiers.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Corporate Contact:
Gail Winslow
Director of Marketing
gwinslow@lexagene.com
978.482.6237
ir@lexagene.com
800.215.1824
Media:
Katie Gallagher
Assistant Vice President, PR and Media Relations
LavoieHealthScience
kgallagher@lavoiehealthscience.com
617.792.3937
Investors:
Sharon Choe
Vice President
LaVoieHealthScience
schoe@lavoiehealthscience.com
857.241.7393
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024